decapeptyl depot novum
decapeptyl depot novum Uses, Dosage, Side Effects, Food Interaction and all others data.
decapeptyl depot novum is a synthetic decapeptide agonist analog of luteinizing hormone releasing hormone (LHRH). Possessing greater potency than endogenous LHRH, triptorelin reversibly represses gonadotropin secretion. After chronic, continuous administration, this agent effects sustained decreases in LH and FSH production and testicular and ovarian steroidogenesis. Serum testosterone concentrations may fall to levels typically observed in surgically castrated men.
The first administration of triptorelin is followed by a transient surge of follicle stimulating hormone (FSH), luteinizing hormone (LH), estradiol,and testosterone. The time, peak and decline of testosterone in the body varies depending on the dose administered. This initial surge is often responsible for worsening of prostate cancer symptoms such as urethral or bladder outlet obstruction, bone pain, spinal cord injury and hematuria in the early stages. A sustained decrease in FSH and LH, and significant reduction of testicular steroidogenesis is usually seen 2-4 weeks post-initiation of therapy. This result is a reduction of serum testosterone to levels which are typically seen in surgically castrated men. Ultimately, tissues and functions that require these hormones become inactive. The effects of triptorelin can usually be reversed once the drug is discontinued.
| Trade Name | decapeptyl depot novum |
| Availability | Prescription only |
| Generic | Triptorelin |
| Triptorelin Other Names | Triptorelin, Triptorelina, Triptoreline, Triptorelinum |
| Related Drugs | Triptodur, Supprelin LA, estradiol, tamoxifen, Premarin, Lupron, Xtandi, leuprolide, Casodex, Zytiga |
| Weight | 3.75mg |
| Type | Solution |
| Formula | C64H82N18O13 |
| Weight | Average: 1311.473 Monoisotopic: 1310.630874772 |
| Protein binding | Triptorelin does not bind to plasma proteins at clinically relevant concentrations. |
| Groups | Approved, Vet approved |
| Therapeutic Class | |
| Manufacturer | Ferring |
| Available Country | Saudi Arabia |
| Last Updated: | September 19, 2023 at 7:00 am |
Uses
decapeptyl depot novum is a GnRH agonist indicated for the palliative treatment of advanced prostate cancer.
decapeptyl depot novum is indicated for the palliative treatment of advanced prostate cancer.
decapeptyl depot novum is also used to associated treatment for these conditions: Advanced Prostate Cancer, Controlled ovarian hyperstimulation therapy
How decapeptyl depot novum works
decapeptyl depot novum is a synthetic agonist analog of gonadotropin releasing hormone (GnRH). Animal studies comparing triptorelin to native GnRH found that triptorelin had 13 fold higher releasing activity for luteinizing hormone, and 21-fold higher releasing activity for follicle-stimulating hormone.
Toxicity
Some of the most commonly reported adverse effects of triptorelin are hot flushes reported in 58.6% of patients, skeletal pain in 12.1%, impotence in 7.1%, and headache in 5.0%. Other reported adverse effects include injection site pain, general body pain, leg pain, fatigue, hypertension, dizziness, diarrhea, vomiting, insomnia, emotional lability, anemia, pruritus, urinary tract infections, and urinary retention. decapeptyl depot novum is classified as Pregnancy Category X and contraindicated in pregnant women or in women who may become pregnant. Hormonal changes caused by triptorelin increase the risk for pregnancy loss. Studies done on pregnant rats demonstrated maternal toxicity and embryo-fetal toxicities.
Food Interaction
No interactions found.decapeptyl depot novum Drug Interaction
Moderate: doxorubicin, tramadolMinor: sulfamethoxazole / trimethoprimUnknown: 5-hydroxytryptophan, paclitaxel protein-bound, aspirin, acetaminophen / dextromethorphan / guaifenesin / phenylephrine, contained in alcoholic beverages , ocular lubricant ophthalmic, aspirin, aspirin, ethanol, omega-3 polyunsaturated fatty acids, acetaminophen, levothyroxine, valproic acid, thiamine, cyanocobalamin, cholecalciferol, goserelin
decapeptyl depot novum Disease Interaction
Moderate: cardiovascular disease, diabetes, QT prolongation, renal/liver dysfunction
Volume of Distribution
After a single IV dose of 0.5mg, the volume of distribution of triptorelin peptide in healthy males was 30 - 33L.
Elimination Route
Following IV administration of triptorelin, triptorelin is completely absorbed.
Half Life
The pharmacokinetics of triptorelin follows a 3 compartment model. The half lives are estimated to be 6 minutes, 45 minutes, and 3 hours respectively.
Clearance
In healthy male volunteers, total clearance of triptorelin was 211.9 mL/min.
Elimination Route
Elimination of triptorelin involves both the kidneys and the liver.
Innovators Monograph
You find simplified version here decapeptyl depot novum
